Posts Images Videos

What We Do


Apalutamide plus abiraterone reduces risk of progression in mCRPC

Profile Pic ikrispharmanet       

   Look Like This Post !
Sign in to make your opinion count.

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!



According to the final analysis from the phase 3 ACIS study came out during the 2021 Genitourinary Cancers Symposium, Adding apalutamide to abiraterone acetate 250 mg and prednisone reduced the risk of radiographic progression or death by 30% in patients with mCRPC receiving androgen deprivation therapy (ADT).



Get Maximum Result To Your Post - Share To All

       Articles     
      Article Categories  

USERONLINE


User online : 97







Leave a Comment

You must be logged in to post a comment.Login Here